BeOne Medicines (NASDAQ:ONC) Announces Earnings Results, Beats Expectations By $0.65 EPS

BeOne Medicines (NASDAQ:ONC) issued its quarterly earnings results on Wednesday. The company reported $2.05 EPS for the quarter, beating the consensus estimate of $1.40 by $0.65, Zacks reports. The company had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.66 billion. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.85%.

Here are the key takeaways from BeOne Medicines’ conference call:

• Q2 results exceeded expectations: Revenue reached $1.7 billion, up 30% year over year, while GAAP diluted EPS increased 144% to $2.05. The company raised 2026 revenue guidance by $300 million and GAAP operating-income guidance by $250 million.
• BRUKINSA continued its strong commercial momentum, generating more than $1.2 billion in global revenue, up 31%, with the highest sustained new-patient starts since launch and growth across all five approved indications. Management cited improving adherence, favorable early treatment duration and supportive real-world survival data.
• Pipeline and regulatory progress accelerated. FDA approval of BEQALZI in relapsed/refractory mantle cell lymphoma and positive Phase III MANGROVE results support a potential chemo-free frontline MCL regimen, with global submissions planned for the second half of 2026; several solid-tumor assets are also moving toward pivotal trials.
• The CELESTIMO 301 zanubrutinib/sonrotoclax regimen did not achieve statistical superiority on the uMRD endpoint versus venetoclax/obinutuzumab. The study will continue to its primary progression-free-survival endpoint, but the result introduces uncertainty despite management’s confidence in eventual PFS superiority.
• BeOne plans substantial continued investment in its pipeline, with 2027 operating expenses expected to grow at a rate similar to recent years. The company also announced a $300 million expansion of its Hopewell, New Jersey manufacturing site, while noting potential future biosimilar competition for XGEVA in its Amgen portfolio.

BeOne Medicines Stock Performance

Shares of BeOne Medicines stock traded up $15.32 on Friday, reaching $345.12. 436,071 shares of the stock were exchanged, compared to its average volume of 281,694. The business has a 50 day moving average price of $295.31 and a two-hundred day moving average price of $308.62. The firm has a market capitalization of $37.87 billion, a price-to-earnings ratio of 60.72 and a beta of 0.49. BeOne Medicines has a twelve month low of $253.95 and a twelve month high of $385.22. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20.

Key Headlines Impacting BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Raised 2026 outlook and strong revenue growth: BeOne Medicines reportedly increased its 2026 guidance after second-quarter revenue surged 30%. Management’s revenue outlook of approximately $6.6 billion to $6.8 billion is above Wall Street’s prior expectation of about $6.5 billion, signaling continued momentum in the company’s oncology portfolio. BeOne Medicines raises 2026 outlook
• Positive Sentiment: Quarterly earnings exceeded estimates: BeOne reported earnings of $2.05 per share, well above the $1.40 analyst consensus, while revenue reached $1.71 billion versus expectations of $1.66 billion. The earnings beat reinforces the company’s improving profitability and supports the bullish reaction. BeOne Medicines Q2 earnings call transcript
• Positive Sentiment: Analysts raised targets: TD Cowen increased its price target to $454 and initiated a Buy rating. Guggenheim raised its target to $430, Truist Financial lifted its target to $418, and Citizens JMP increased its target to $405; all maintained bullish ratings. RBC made a smaller reduction to $450 but retained an Outperform rating. Collectively, the revisions indicate analysts see meaningful upside after the earnings report. Analyst price target updates
• Neutral Sentiment: Insider sale appears administrative: CFO Aaron Rosenberg sold 1,157 shares worth roughly $362,000. The filing said the transaction covered tax withholding obligations related to vested equity awards, making it a limited bearish signal. BeOne Medicines SEC insider filing

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Guggenheim upped their price objective on shares of BeOne Medicines from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Thursday. Citigroup restated an “outperform” rating on shares of BeOne Medicines in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a research report on Friday, July 17th. Nomura upgraded BeOne Medicines to a “strong-buy” rating in a research note on Monday, July 27th. Finally, TD Cowen lifted their target price on BeOne Medicines from $424.00 to $454.00 and gave the company a “buy” rating in a research note on Thursday. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $400.00.

Insider Buying and Selling at BeOne Medicines

In other BeOne Medicines news, CEO John Oyler sold 61,397 shares of the company’s stock in a transaction that occurred on Tuesday, July 21st. The stock was sold at an average price of $317.67, for a total value of $19,503,984.99. Following the sale, the chief executive officer owned 9,180 shares in the company, valued at approximately $2,916,210.60. This represents a 86.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Rosenberg sold 1,157 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $312.71, for a total transaction of $361,805.47. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 345,561 shares of company stock worth $105,625,947 over the last ninety days. 6.19% of the stock is owned by insiders.

Institutional Trading of BeOne Medicines

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ONC. Siren L.L.C. boosted its stake in shares of BeOne Medicines by 1.4% during the 4th quarter. Siren L.L.C. now owns 500,000 shares of the company’s stock worth $151,905,000 after acquiring an additional 7,010 shares in the last quarter. Morgan Stanley boosted its position in BeOne Medicines by 23.9% during the fourth quarter. Morgan Stanley now owns 437,661 shares of the company’s stock worth $132,966,000 after purchasing an additional 84,367 shares in the last quarter. Bank of America Corp DE grew its holdings in BeOne Medicines by 23.5% in the third quarter. Bank of America Corp DE now owns 345,256 shares of the company’s stock valued at $117,629,000 after purchasing an additional 65,763 shares during the period. Man Group plc grew its holdings in BeOne Medicines by 18.9% in the fourth quarter. Man Group plc now owns 248,514 shares of the company’s stock valued at $75,501,000 after purchasing an additional 39,498 shares during the period. Finally, BNP Paribas Financial Markets purchased a new stake in shares of BeOne Medicines in the second quarter valued at approximately $38,337,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.